AUSTIN, Texas, March 23, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that that Dr. Dirk Arnold, a leading international specialist in gastrointestinal (GI) cancers, has joined the Company’s Scientific Advisory Board (SAB). Dr. Arnold will work with XBiotech to help navigate clinical development and communicate the findings for the Company’s lead product candidate in advanced colorectal cancer. Dr. Arnold’s main research interests include the treatment of GI cancers with a focus on targeted and immunotherapies, among others. Importantly, his special interest in clinical research methodologies and benefit evaluation are relevant to one of XBiotech’s lead oncology programs, which has involved the development of a novel measure of clinical efficacy in advanced cancer patients.
Dr. Arnold is a member of the following organizations: Executive Board of the European Society for Medical Oncology (ESMO) and European Cancer Organization (ECCO); chairman of Colorectal Cancer Study Group of the German Society of Clinical Oncology (AIO); American Society of Clinical Oncology (ASCO); Task Force Colorectal Cancer of the European Organization for Research and Treatment of Cancer (EORTC) GI study group; German Cancer Society; and the German Society of Haematology and Medical Oncology (DGHO). He is currently Director of the Insituto CUF de Oncologia in Lisbon, Portugal.
About True Human™ Therapeutic Antibodies
XBiotech’s True Human™ antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech’s True Human antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability.
About XBiotech
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Contact
Ashley Oteroaotero@xbiotech.com
512-386-2930
XBiotech, Inc
